Reviewing Fulcrum Therapeutics (NASDAQ:FULC) and CytomX Therapeutics (NASDAQ:CTMX)

Fulcrum Therapeutics (NASDAQ:FULC) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Valuation and Earnings

This table compares Fulcrum Therapeutics and CytomX Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulcrum Therapeutics	$80.00 million	3.51	-$74.88 million	($1.21)	-3.04
CytomX Therapeutics	$76.20 million	6.63	-$17.37 million	($0.50)	-4.64

CytomX Therapeutics has lower revenue, but higher earnings than Fulcrum Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

89.8% of Fulcrum Therapeutics shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 7.3% of Fulcrum Therapeutics shares are owned by company insiders. Comparatively, 3.8% of CytomX Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations for Fulcrum Therapeutics and CytomX Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulcrum Therapeutics	4	7	1	0	1.75
CytomX Therapeutics	1	1	9	1	2.83

Fulcrum Therapeutics currently has a consensus target price of $8.20, suggesting a potential upside of 122.83%. CytomX Therapeutics has a consensus target price of $11.90, suggesting a potential upside of 412.93%. Given CytomX Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe CytomX Therapeutics is more favorable than Fulcrum Therapeutics.

Profitability

This table compares Fulcrum Therapeutics and CytomX Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fulcrum Therapeutics	N/A	-25.38%	-24.15%
CytomX Therapeutics	-435.21%	-38.46%	-30.33%

Volatility and Risk

Fulcrum Therapeutics has a beta of 2.63, indicating that its stock price is 163% more volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 2.21, indicating that its stock price is 121% more volatile than the S&P 500.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

About CytomX Therapeutics

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.